In the past 52-week period, shares of Nektar Therapeutics (NASDAQ:NKTR) have moved within the range of $11.41 to $54.95. On the stock’s most recent trading day, the company’s shares ended the regular session at $53.99, which is 1.75% lower than its 52-week high.
Nektar Therapeutics (NKTR) has demonstrated a 20-day simple moving average (SMA) of 37.92%, and a 50-day SMA of 80.90%. This public company’s current market capitalization stands at $8.44 billion.Analyzing Consensus Estimates, Sales Revenue and Net Income
Checking the amount of enthusiasm that Wall Street analysts hold for a particular stock is crucial when thinking about entering a position. According to the latest data, the consensus recommendation for Nektar Therapeutics (NKTR) is Outperform.
Public companies normally post earnings and revenue results that fall somewhat above or below the average Wall Street estimate. In the most recent quarterly financial report, for the quarter ending Sep. 2017, Nektar Therapeutics (NKTR) delivered a 30.35% surprise with its net revenue. Sales reached $0.15 billion during the three-month period, compared to the average analyst estimate of $0.12 billion.Ownership at Nektar Therapeutics (NKTR), According to Most Recent SEC Filings
A publicly-traded organization’s latest 13F filings tell us important details about its institutional ownership. Nektar Therapeutics (NKTR) has 0 billion shares outstanding currently, 98.21% of which belong to institutional investors. Those institutional holdings amount to $8.37 billion.
Additionally, according to the most recent 13F filing from Nektar Therapeutics (NKTR), there were 23 new positions totaling 1,207,179 shares of the company’s stock. There were 15 sold out positions, on the other hand, totaling 1,185,979 shares.Short, Medium and Long Term Indicators
Assessing the average trade volume of a public company’s stock in the short, medium and long term is helpful to gain an understanding of trading activity and investor sentiment. Nektar Therapeutics (NKTR) has had a 20-day average volume of 3,908,185 shares, with an average of 80% of short term indicators pointed at Buy.
The stock’s 50-day average volume has been 2,263,452 shares, with an average of 100% of medium term indicators pointing toward Buy. Finally, its 100-day average volume is 1,717,790 shares with 100% of long-term indicators pointing to Buy.